Preclinical study shows how commonly prescribed drugs for Alzheimer’s disease interfere with the activity of the tau aggregation inhibitor hydromethylthionine

Preclinical study shows how commonly prescribed drugs for Alzheimer’s disease interfere with the activity of the tau aggregation inhibitor hydromethylthionine

ABERDEEN, Scotland and Singapore, 04 March, 2020 – Today, TauRx Therapeutics announced the publication of a study in an Alzheimer’s disease (AD) mouse model which demonstrates that drugs currently used to manage the symptoms of the disease interfere with the activity of a drug with an entirely unrelated mode of action. The preclinical research, published online in Current Alzheimer Research1 (abstract available here; manuscript available here), showed that prior treatment with rivastigmine (an acetylcholinesterase inhibitor) negatively affected the pharmacological activity of hydromethylthionine which acts on the tau aggregation pathology of AD.

Read more here.

Press Release Preclinical study March 2020

Today, TauRx Therapeutics announced the publication of a study in an Alzheimer’s disease (AD) mouse model